Previous 10 | Next 10 |
2024-03-19 17:37:35 ET Gainers: Taysha Gene Therapies ( TSHA ) +32% . Canopy Growth Corporation ( CGC ) +14% . Sarcos Technology and Robotics ( STRC ) +12% . Adicet ( ACET ) +6% . Bridger Aerospace Group Holdings ( BAER ) +4%...
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on...
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
2024-02-27 12:43:51 ET A California-based %Biotech company is turning heads during Tuesday’s session after the company announced it entered into an exclusive licensing agreement for newly engineered double-stranded DNA ligase with Roche, according to a press release. Shares o...
2024-02-27 09:06:36 ET DENVER, Colo., Feb 27, 2024 ( 247marketnews.com )- The following companies are mentioned; Codexis (NASDAQ: CDXS ), Kraig Biocraft Laboratories (OTCQB: KBLB ), Janux Therapeutics (NASDAQ: JANX ), TransMedics Group (NASDAQ: TMDX ), and Viking Therape...
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for...
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44 th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts. Management will par...
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder ...
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis...
2024-02-13 16:12:15 ET More on Codexis Codexis and Aldevron sign exclusive licensing deal for Codex HiCap RNA polymerase Seeking Alpha’s Quant Rating on Codexis Read the full article on Seeking Alpha For further details see: Codexis gets $40M finan...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced it has...
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic man...
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotid...